“…Besides, previous investigations have demonstrated that MF was a xanthonoid with anti-inflammatory capacity, and it was reported to be a promising therapeutic drug for OA (Luczkiewicz et al, 2014;Saha et al, 2016;Qu et al, 2017b;Garrido-Suarez and Garrido, 2019). Previous investigations elucidated that MF markedly suppressed the productions of IL-6, IL-1b, and TNF-a in LPS-triggered primary hepatocytes, BALB/c mice mammary gland, and peritoneal macrophages (Jeong et al, 2014;Pan et al, 2016;Qu et al, 2017a). Furthermore, an earlier research revealed that PT-MF remarkably decreased the expression of Cox-2, iNOS and TNF-a, and the generation of ROS in LPS-evoked RAW 264.7 cells (Bulugonda et al, 2017).…”